Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations

Green, Claire L., Tawana, Kiran, Hills, Robert Kerrin, Bodor, Csaba, Fitzgibbon, Jude, Inglott, Sarah, Ancliff, Phil, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2013. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. British Journal of Haematology 161 (5) , pp. 701-705. 10.1111/bjh.12317

Full text not available from this repository.


GATA2 mutations have recently been reported in acute myeloid leukaemia (AML) patients with CEBPA-double mutations. To explore their impact on this favourablerisk disease, we determined GATA2 status in 153 sporadic AML patients and three members of a germ-line CEBPA-mutant family at AML presentation. Overall, 27% (15/55) CEBPA-double, 16% (7/43) CEBPA-single and 0% (0/55) normal karyotype/ CEBPA-wild-type patients were GATA2-mutant. All familial AML patients acquired both a second CEBPA and a GATA2 mutation. CEBPA and GATA2 mutant levels indicated that both mutations were likely to be early events in leukaemogenesis. GATA2 status did not impact on the favourable outcome of CEBPAdouble/ FLT3-inernal tandem duplication-negative patients.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Wiley-Blackwell
ISSN: 0007-1048
Last Modified: 19 Oct 2019 02:57

Citation Data

Cited 9 times in Google Scholar. View in Google Scholar

Cited 32 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item